NCT00527566View on ClinicalTrials.gov

Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions

Churg Strauss Syndrome

Interventions

BIOLOGICAL

Mepolizumab

IV mepolizumab, 750 mg

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Brigham and Women's Hospital

OTHER